UCSD Moores EAB: A leak to The Cancer Letter derailed the iterative process

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dear Editor, 

The UCSD Moores Cancer Center External Advisory Board is extremely disappointed in the commentary included in the most recent issue of The Cancer Letter regarding MCC (The Cancer Letter, June 2, 2023).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
EAB members, UCSD Moores Cancer Center
EAB members, UCSD Moores Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives. 
NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.
EAB members, UCSD Moores Cancer Center
EAB members, UCSD Moores Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login